报价延迟最少15分钟:2025/01/21 05:37 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
342.41 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-28.08/12.47
|
|
企业价值
11.01B
|
| 资产负债 |
|
每股账面净值
267.45
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
2.67B
|
|
每股收益
97.17
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/01/21 05:37 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |